69 Karnataka MLAs Claimed ₹7.47 Crore in Medical Bills, RTI Data Shows
RTI data shows 69 Karnataka MLAs claimed ₹7.47 crore in medical reimbursements from 2023 to 2026. Top claims, the rules and what is unknown.
69 Karnataka MLAs Claimed ₹7.47 Crore in Medical Bills, RTI Data Shows
RTI data shows 69 Karnataka MLAs claimed ₹7.47 crore in medical reimbursements from 2023 to 2026. Top claims, the rules and what is unknown.
Healthleap Raises $38M for Its AI That Flags Hospital Patients Who May Need a Closer Look
Healthleap raises $38M in seed and Series A funding for AI that screens hospital inpatients for malnutrition and delirium. Claims and caveats.
Change Lifestyle Before Giving Children Weight-Loss Medication, WHO Says
WHO’s first childhood obesity guidelines rule out weight-loss drugs under 10 and put lifestyle care before medicine for teens. What families should know.
Measles Case Confirmed in Allegheny County, Possible Exposure at McCandless Target
An unvaccinated child has measles in Allegheny County, with possible exposure at the McCandless Target on 1 October. Who is at risk and what to do now.
AnnJi Advances AJ201 into Phase 3 Trial for Kennedy’s Disease
AnnJi moves AJ201 (rosolutamide) into the pivotal Phase 3 ROMA-KD trial for spinal and bulbar muscular atrophy, also called Kennedy disease.
AAVantgarde Reports Updated Gene Therapy Data for Usher Syndrome and Stargardt Disease
AAVantgarde reports early AAVB-081 results in Usher 1B (7 of 12 gained a line of vision) and preclinical AAVB-039 data for Stargardt disease.
Genmab Reports Positive Rina-S Data in Platinum-Resistant Ovarian Cancer
Genmab reports a 45.9% response rate and 12.1-month response duration for Rina-S in platinum-resistant ovarian cancer. Data, safety and what is next.
BD to Invest $3 Billion in U.S. Medical Device Manufacturing, With Over $1 Billion Cited for Nebraska
BD plans a $3 billion US manufacturing expansion inside a $19 billion pledge tied to tariff relief. What is confirmed, and what is not.
Samfara Makes Debut Buyout With Danish API Maker Chr. Olesen Synthesis
London-based Samfara has made its first investment, backing a Danish maker of controlled-substance APIs. How the buyout works and what to watch.
